Welcome to visit our booth #701 at 15th World ADC annual meeting in San Diego November 5-6th! Looking forward to meeting you!
Zencore Biologics
制药业
Germantown,Maryland 972 位关注者
Pursue the Truth, Commit the Utmost, Strive for Excellence
关于我们
Zencore Biologics is a CDMO provider headquartered in Shanghai, China. Zencore has an R&D facility located in Maryland, United States. Zencore provides one-stop-shop services for biologics development from CMC to commercial manufacturing and customized cell culture medium services for mammalian cell-based protein production. Zencore supports the R&D and production of biologics for our clients around the world. The services and solutions provided include: ? Biologics CDMO ? Antibody drug conjugate (ADC) CDMO ? Cell culture medium support: the development & manufacturing ? Analytical development and characterization services ? QC testing & regulatory filings With two CDMO facilities of 600,000 sq ft in total, Zencore provides a pilot scale production with 4×200L and 1×500L single use bioreactors, and the state-of-the-art commercial GMP manufacturing services with 3×2,000L single use and 3×5,000L stainless steel bioreactors in separate production suites, followed by downstream purification, formulation, and fill and finish lines.
- 网站
-
https://zencorebio.com/
Zencore Biologics的外部链接
- 所属行业
- 制药业
- 规模
- 501-1,000 人
- 总部
- Germantown,Maryland
- 类型
- 私人持股
- 创立
- 2017
- 领域
- One-Stop-Shop Biologics CDMO、ADC、CDO、CMO、Cell line development和CDMO
地点
Zencore Biologics员工
动态
-
Congratulations?to?Biosion?on?the?approval?of?IND?application?for?BSI-082?by?FDA.?BSI-082?a?fully?human?anti-SIRPα?antagonistic?monoclonal?antibody?(mAb)?with?portential?broad?combotherapies?for?the?treatment?of?hematologic?and?solid?tumors. As?the?CMC?service?provider?of?Biosion,?we?provided?CMC?technology?development?services?from?DNA?to?IND?application?to?help?BSI-082?new?drug?project?IND?approval. Zencore?Biologics?will?continue?to?adhere?to?providing?high-quality?and?efficient?comprehensive?CDMO?services?for?global?partners. Please read the press release: https://lnkd.in/gKyDg34t #CDMO?#Biologics?#Antibody #FDAapproval
Exciting news! The FDA has cleared Biosion's IND application for BSI-082, a novel anti-SIRPα monoclonal antibody with potential for treating hematologic and solid tumors. This marks a major milestone for Biosion's innovative pipeline. #FDAApproval #MedicalInnovation #BioTech https://lnkd.in/g-B-AKpv